Advertisement

August 17, 2020

Sirtex Medical Partners With Magle Chemoswed to Develop Imaging Agent

August 17, 2020—Sirtex Medical US Holdings, Inc. announced a collaboration with Magle Chemoswed, a Sweden-based contract development and manufacturing organization.

The development and commercial agreement grants Sirtex global use of Magle Chemoswed’s technology to develop a novel imaging agent for use in interventional oncology. Sirtex will have the exclusive license and commercialization rights in the defined field of use. Magle Chemoswed maintains rights to its technology platform and to exclusively manufacture the product for supply to Sirtex. The development program will begin in Q3 2020.

Advertisement


August 17, 2020

Postmarket PATHFINDER I Registry Commences for AngioDynamics’ Auryon Atherectomy System

August 17, 2020

FDA Approves IDE for Pivotal TRIOMPHE Study of Endospan’s Nexus Aortic Arch Stent Graft System